Valeant (VRX) Misses, Lowers, Delays - Wells Fargo's Maris
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Wells Fargo analyst David Maris offered some comments on Valeant Pharmaceuticals (NYSE: VRX) following its Q3 miss and lower outlook.
Maris commented, "Valeant reported 3Q results that missed expectations. Revenue of $2.48 billion missed our estimate of $2.74 billion and consensus of $2.51 billion. Valeant's adjusted EPS of $1.55 missed our $1.95 estimate and consensus of $1.75. We had assumed Valeant would experience some tailwinds from pricing, higher rebates, and increased prior-authorizations; however, it appears Valeant's core business continue to deteriorate, as we had feared, and the 2H acceleration management predicted is not materializing. As we had predicted, Valeant lowered its full-year 2016 guidance. Valeant now expects full-year adjusted EPS in the range of $5.50-$5.60, a revision of approximately $1.40 at the midpoint and equates to an implied 4Q adjusted EPS of $1.19 vs. current consensus of $2.04. As we mentioned in our preview, current consensus for 2017 adjusted EPS is currently $7.60 and is at significant risk, in our opinion. We note that adjusted EPS benefited from SG&A cuts and addbacks of items like legal expenses, which are cash expenses and, to us, are neither one time nor unexpected but rather reflective of the business."
The firm said cash from operations remains a concern for them. Valeant generated approximately $570 million in cash from operations in 3Q, approximately $163 million less than a year ago, and approximately $50 million less than two years ago. "We do not quite understand how a business that spent more than $15 billion to acquire assets experiences deteriorating cash generation," he said.
Valeant recognized a goodwill impairment charge of $1.05 billion in the quarter, which it attributes largely to Salix.
The firm maintained an Underperform rating and $17-$22 valuation range.
Shares of Valeant Pharmaceuticals closed at $19.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Sees 'Encouraging' Short-Term Set-Up in Valeant (VRX)
- Skyworks Solutions (SWKS) PT Raised to $105 at Oppenheimer Following 1Q Report
- UPDATE: SunTrust Robinson Humphrey Upgrades Regency Centers (REG) to Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesWells Fargo, Definitive Agreement, David Maris
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!